Please Wait.....
Report
H. Lundbeck AS (HLUN A:CPH) Strategic SWOT Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Operational KPI's, and Recent Trends
Company Report I 2024-11-22 I 84 Pages I Quaintel Research
Report Summary
Year End Offer - Buy Now and get an updated version of this Report at no extra cost within 30 days of the release of Company's next Annual Report. (Offer expires on 31st Dec 2024)
H. Lundbeck AS (HLUN A:CPH) Strategic SWOT Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Operational KPI's, and Recent Trends Report is a comprehensive and easily accessible overview of H. Lundbeck AS's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about H. Lundbeck AS including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses H. Lundbeck AS's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of H. Lundbeck AS's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by H. Lundbeck AS enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
H. Lundbeck A/S (commonly known simply as Lundbeck) is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company's products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine. The company headquartered in Copenhagen, Denmark and has approximately 5,600 employees in more than 50 countries, and their products are registered in more than 100 countries. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US and other countries.
H. Lundbeck AS in the News:-
- 31-Oct-2024 - Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti (eptinezumab) in migraine prevention
- 23-Oct-2024 - Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth
- 14-Oct-2024 - Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline
- 03-Oct-2024 - Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease
- 27-Sep-2024 - Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the H. Lundbeck AS's internal and external factors through SWOT analysis and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company H. Lundbeck AS:
- H. Lundbeck AS PESTLE Analysis
- H. Lundbeck AS Value Chain Analysis
- H. Lundbeck AS Porter's Five Forces Analysis
- H. Lundbeck AS VRIO Analysis
- H. Lundbeck AS BCG Analysis
- H. Lundbeck AS Segmentation, Targeting and Positioning (STP) Analysis
- H. Lundbeck AS Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
H. Lundbeck AS-Key Company Facts 8
H. Lundbeck AS- Company Description 9
H. Lundbeck AS- Top Executives 10
H. Lundbeck AS- Head Office & Locations 11
Head Office - Country 11
H. Lundbeck AS- Productsand Services 12
Products 12
H. Lundbeck AS- Corporate Strategy 13
H. Lundbeck AS- Business Description 19
Pharmaceutical 20
H. Lundbeck AS- ESG Spotlight 21
Environment 21
Social 22
Corporate Governance 23
H. Lundbeck AS- SWOT Analysis 24
Overview 24
Strengths 26
Weaknesses 28
Opportunities 30
Threats 33
H. Lundbeck AS- Financial Deep Dive 35
Share Price Trend - Nov-2023 to Nov-2024 (Average Share Closing Price) 35
Profit and Loss Statement 37
Summary of Profit and Loss Statement 37
Balance Sheet 39
Summary of Balance Sheet 39
Cash Flow Statement 41
Summary of Cash Flow Statement 41
Key Financial Ratio Analysis 43
H. Lundbeck AS- Ratio Charts 44
Activity Ratio Charts 44
Growth Ratios Charts 45
Leverage Ratio Charts 46
Liquidity Ratio Charts 47
Profitability Ratio Charts 48
Competing Players 49
Snapshot of Competing Players 50
Abbott Laboratories 50
Key Company Facts 50
Company Description 50
Snapshot of Competing Players 51
Eli Lilly and Company 51
Key Company Facts 51
Company Description 51
Snapshot of Competing Players 52
Novo Nordisk A/S 52
Key Company Facts 52
Company Description 52
Snapshot of Competing Players 53
Takeda Pharmaceutical Company Limited 53
Key Company Facts 53
Company Description 53
Snapshot of Competing Players 54
GlaxoSmithKline Pharmaceuticals Ltd 54
Key Company Facts 54
Company Description 54
H. Lundbeck AS - In the News 55
31-Oct-2024 -Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti (eptinezumab) in migraine prevention 55
23-Oct-2024 -Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth 56
14-Oct-2024 -Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline 56
03-Oct-2024 -Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease 57
27-Sep-2024 -Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders 58
20-Aug-2024 -Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator 58
15-May-2024 -Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024 59
13-May-2024 -Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck 60
18-Mar-2024 -How Lundbeck used AI to qualify new drug targets for headache disorders 60
15-Mar-2024 -Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage 63
05-Mar-2024 -Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders 65
23-Feb-2024 -Lundbeck announces changes to Executive Management 67
16-Feb-2024 -Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 68
07-Feb-2024 -Lundbeck reached record revenue of DKK 20 billion in 2023 with strong growth momentum set to continue in 2024 69
05-Feb-2024 -Dianne Hol appointed new Executive Vice President People & Organization at Lundbeck 69
31-Jan-2024 -Lundbeck announces supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial 71
20-Dec-2023 -Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 72
H. Lundbeck AS - Key Deals 73
26-Sep-2024 - Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery 73
25-Jun-2024 - Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) 74
21-Feb-2023 - EHDEN not-for-profit and Lundbeck collaborate on first research programme, in Neuroscience 75
04-Aug-2021 - Lundbeck enters strategic research collaboration with Rgenta Therapeutics on therapies targeting RNA 76
Appendix 77
Definitions 77
SWOT Analysis 77
PESTLE Analysis 77
Value Chain Analysis 77
ESG Spotlight 77
Financial Deep Dive 77
Financial Ratios- 78
Activity Ratios 78
Growth Ratios 79
Leverage Ratios 80
Liquidity Ratios 81
Market Ratios 82
Profitability Ratios 82
Research Methodology 83
Disclaimer 84
Contact Us 84
Tables
Table 1: H. Lundbeck AS - Company Facts
Table 2: H. Lundbeck AS - Digital Presence
Table 3: H. Lundbeck AS - Top Executives
Table 4: H. Lundbeck AS- Products
Table 5: H. Lundbeck AS - Share Price Trend - Nov-2023to Nov-2024
Table 6: H. Lundbeck AS - Ratio Analysis -2020-2023
Table 7: H. Lundbeck AS - Competing Players
Table 8: Competing Players - Abbott Laboratories - Key Company Facts
Table 9: Competing Players - Eli Lilly and Company - Key Company Facts
Table 10: Competing Players - Novo Nordisk A/S - Key Company Facts
Table 11: Competing Players - Takeda Pharmaceutical Company Limited - Key Company Facts
Table 12: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Key Company Facts
Charts
Figure 1: H. Lundbeck AS- SWOT Analysis 25
Figure 2: H. Lundbeck AS-Average Share Price Trend - Nov-2023to Nov-2024 36
Figure 3: H. Lundbeck AS- Profit and Loss Statement -2020-2023 38
Figure 4: H. Lundbeck AS- Balance Sheet-2020-2023 40
Figure 5: H. Lundbeck AS- Cash Flow Statement 2020-2023 42
Figure 6: H. Lundbeck AS- Activity Ratio Charts 44
Figure 7: H. Lundbeck AS- Growth Ratio Charts (Value %) 45
Figure 8: H. Lundbeck AS- Leverage Ratio Charts 46
Figure 9: H. Lundbeck AS- Liquidity Ratio Charts 47
Figure 10: H. Lundbeck AS- Profitability Ratio Charts (Value %) 48
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security